Antoni Ribas - Arcus Biosciences Independent Director
| RCUS Stock | USD 15.70 0.20 1.29% |
Director
Antoni Ribas is Independent Director of Arcus Biosciences since 2020.
| Age | 53 |
| Tenure | 4 years |
| Address | 3928 Point Eden Way, Hayward, CA, United States, 94545 |
| Phone | 510 694 6200 |
| Web | https://www.arcusbio.com |
Arcus Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.1742) % which means that it has lost $0.1742 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5487) %, meaning that it created substantial loss on money invested by shareholders. Arcus Biosciences' management efficiency ratios could be used to measure how well Arcus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.29 in 2024. Return On Capital Employed is likely to drop to -0.39 in 2024. At this time, Arcus Biosciences' Net Tangible Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 113 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 211.7 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Nancy Hawthorne | Tscan Therapeutics | 66 | |
| James Daly | Madrigal Pharmaceuticals | N/A | |
| Lynn Seely | Blueprint Medicines Corp | 59 | |
| Mark Goldberg | Blueprint Medicines Corp | 63 | |
| Sinclair Dunlop | Apellis Pharmaceuticals | 46 | |
| Keith Hughes | Tscan Therapeutics | 70 | |
| Rene Russo | X4 Pharmaceuticals | 42 | |
| David Downes | Tscan Therapeutics | 76 | |
| Murray Stewart | X4 Pharmaceuticals | 57 | |
| Charles Rowland | Blueprint Medicines Corp | 59 | |
| Gary Bridger | X4 Pharmaceuticals | N/A | |
| Isaac Blech | X4 Pharmaceuticals | N/A | |
| Ian Clark | AVROBIO | 57 | |
| Jerome Zeldis | PTC Therapeutics | 68 | |
| MD FACP | Hepion Pharmaceuticals | N/A | |
| Stephen Knight | Blueprint Medicines Corp | 55 | |
| Frederick Craves | Madrigal Pharmaceuticals | 72 | |
| Lonnel Coats | Blueprint Medicines Corp | 53 | |
| David Southwell | PTC Therapeutics | 57 | |
| Nicholas Lydon | Blueprint Medicines Corp | 61 | |
| Timothy Block | Hepion Pharmaceuticals | 61 | |
Management Performance
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.17 |
Arcus Biosciences Leadership Team
Elected by the shareholders, the Arcus Biosciences' board of directors comprises two types of representatives: Arcus Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arcus. The board's role is to monitor Arcus Biosciences' management team and ensure that shareholders' interests are well served. Arcus Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arcus Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer MBA, Chief Officer | ||
| Juan Jaen, President, Co-Founder, Director | ||
| Nicole Lambert, Director | ||
| Patrick Machado, Independent Director | ||
| Steve Young, Vice President - Technology | ||
| Jason Barker, Vice President - Finance | ||
| Jennifer Jarrett, Chief Business and Financial Officer | ||
| Michael Quigley, Director | ||
| Linda Higgins, Director | ||
| Alexander Azoy, VP Officer | ||
| David Beier, Independent Director | ||
| Antoni Ribas, Independent Director | ||
| Holli Kolkey, Vice Communications | ||
| Carolyn JD, General Secretary | ||
| Katherine Bock, Vice Strategy | ||
| Andrew Perlman, Independent Director | ||
| Rekha Hemrajani, CFO, COO | ||
| Ulrike Schindler, Vice President - Biology | ||
| Robert II, Principal CFO | ||
| Eric Hoefer, Chief Commercial Officer & Head of Business Development | ||
| Stephen Young, Senior Biology | ||
| Jonathan Yingling, Chief Officer | ||
| Terry Rosen, Chairman of the Board, Chief Executive Officer, Co-Founder | ||
| Yvonne Gehring, Senior Operations | ||
| Steven Chan, Vice President of Finance and principal accounting officer | ||
| Robert Goeltz, Chief Financial Officer, Principal Financial and Accounting Officer | ||
| Yasunori Kaneko, Lead Independent Director | ||
| David Lacey, Independent Director | ||
| Kristen Hege, Director | ||
| Kathryn Falberg, Independent Director | ||
| Carolyn Tang, General Counsel | ||
| Jay Powers, Senior Vice President - Drug Discovery | ||
| Merdad Parsey, Director | ||
| Christopher Garcia, CoFounder Board | ||
| William Grossman, Chief Medical Officer |
Arcus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arcus Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (2.62) % | ||||
| Operating Margin | (2.94) % | ||||
| Current Valuation | 770.4 M | ||||
| Shares Outstanding | 90.95 M | ||||
| Shares Owned By Insiders | 41.13 % | ||||
| Shares Owned By Institutions | 59.55 % | ||||
| Number Of Shares Shorted | 6.84 M | ||||
| Price To Earning | 27.69 X |
Currently Active Assets on Macroaxis
| LAAC | Lithium Americas Corp | |
| F | Ford Motor | |
| CHPT | ChargePoint Holdings | |
| AXL | American Axle Manufacturing | |
| ICLN | iShares Global Clean |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Arcus Stock analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Arcus Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcus Biosciences. If investors know Arcus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.15) | Revenue Per Share 1.581 | Quarterly Revenue Growth (0.09) | Return On Assets (0.17) | Return On Equity (0.55) |
The market value of Arcus Biosciences is measured differently than its book value, which is the value of Arcus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcus Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcus Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcus Biosciences' market value can be influenced by many factors that don't directly affect Arcus Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcus Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcus Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.